MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.

Autor: Heugenhauser J; Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Galijasevic M; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Neuroimaging Core Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria., Mangesius S; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Neuroimaging Core Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria., Goebel G; Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, 6020 Innsbruck, Austria., Buchroithner J; Department of Neurosurgery, Johannes Kepler University, 4020 Linz, Austria., Erhart F; Department of Neurosurgery, Medical University of Vienna, 1090 Vienna, Austria.; Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria., Pichler J; Department of Internal Medicine and Neurooncology, Johannes Kepler University, 4020 Linz, Austria., Widhalm G; Department of Neurosurgery, Medical University of Vienna, 1090 Vienna, Austria., Stockhammer G; Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Iglseder S; Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Freyschlag CF; Department of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, Austria., Oberndorfer S; Department of Neurology, Landsteiner Private University, 3100 St. Pölten, Austria., Bordihn K; Department of Neurosurgery, Paracelsus Private Medical University, 5020 Salzburg, Austria., von Campe G; Department of Neurosurgery, Medical University of Graz, 8036 Graz, Austria., Czech T; Department of Neurosurgery, Medical University of Vienna, 1090 Vienna, Austria., Surböck B; Department of Neurology, Klinik Favoriten, Wiener Gesundheitsverbund, 1100 Vienna, Austria., Urbanic Purkart T; Department of General Neurology and Neuroradiology, Vascular and Interventional Radiology, Medical University of Graz, 8036 Graz, Austria., Marosi C; Clinical Division of Medical Oncology, Department for Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria., Felzmann T; Activartis Biotech GmbH, 1160 Vienna, Austria., Nowosielski M; Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2022 Mar 20; Vol. 14 (6). Date of Electronic Publication: 2022 Mar 20.
DOI: 10.3390/cancers14061579
Abstrakt: Introduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall survival (OS). Methods: 76 patients enrolled in a multicenter phase II trial receiving standard of care (SOC, n = 40) or SOC + Audencel vaccine (n = 36) were included. MRI scans were evaluated using MacDonald, RANO, Vol-RANO, mRANO, Vol-mRANO and iRANO criteria. Tumor volumes (T1 contrast-enhancing as well as T2/FLAIR volumes) were calculated by semiautomatic segmentation. The Kruskal-Wallis-test was used to detect differences in PFS among the assessment criteria; for correlation analysis the Spearman test was used. Results: There was a significant difference in median PFS between mRANO (8.6 months) and Vol-mRANO (8.6 months) compared to MacDonald (4.0 months), RANO (4.2 months) and Vol-RANO (5.4 months). For the vaccination arm, median PFS by iRANO was 6.2 months. There was no difference in PFS between SOC and SOC + Audencel. The best correlation between PFS/OS was detected for mRANO (r = 0.65) and Vol-mRANO (r = 0.69, each p < 0.001). A total of 16/76 patients developed a pure T2/FLAIR progressing disease, and 4/36 patients treated with Audencel developed pseudoprogression. Conclusion: When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje